Related Experiment Videos

Infliximab Versus Adalimumab in Patients with Biologic-Naïve Crohn's Disease: Is the Difference Real?

Tamara Mogilevski¹, Miles P Sparrow^2,3

¹Department of Gastroenterology, The Alfred Hospital, 55 Commercial Road, Melbourne, 3004, Australia.

Digestive Diseases and Sciences

|February 9, 2018

Abstract

No abstract available in PubMed .

Related Concept Videos

Articles linked to this work by shared authors, journal, and citation graph.

Pharmacological management of Crohn's-like disease of the pouch: a phenotype-based review.

Expert opinion on pharmacotherapy·2026

The introduction of an intestinal ultrasound service is associated with significantly reduced endoscopy usage in an inflammatory bowel disease service-the SCOPELESS study.

Journal of Crohn's & colitis·2026

Evaluating treatment to a target of transmural healing in patients with moderately to severely active Crohn's disease: rationale, design and protocol for the randomised controlled VECTORS trial.

BMJ open gastroenterology·2026

Therapeutic Drug Monitoring of the Subcutaneous Formulations of Infliximab and Vedolizumab-Current Knowledge and Future Directions.

Journal of clinical medicine·2026

A Critical Review of Persistent Gastrointestinal and Extraintestinal Symptoms in Quiescent Inflammatory Bowel Disease: Time for Greater Precision and Clarity.

Journal of gastroenterology and hepatology·2026

Australian Real-World Effectiveness and Safety of Ustekinumab for the Treatment of Crohn's Disease: Results of the AURORA Study, Including the ANZIBD Consortium.

JGH open : an open access journal of gastroenterology and hepatology·2025

See all related articles